Serum soluble intercellular adhesion molecule-1 in MS: relation to clinical and Gd-MRI activity and to rIFNβ-1b treatment

Abstract

The validity of serum sICAM-1 levels to assess Multiple Sclerosis (MS) activity was evaluated in 49 untreated definite relapsing-remitting (RR) patients. sICAM-1 levels were significantly (P = 0.0009) higher in the `clinically active' group (No 22) than in the `clinically inactive' (No 27), whereas no different values were found between patients with Gd-enhancing lesions at MRI (Gd-positive) (No 32) and patients without such lesions (Gd-negative) (No 17) independently of their clinical activity. Among the `clinically active' MS, the Gd-positive (No 16) subgroup showed significant (P50.05) lower sICAM-1 levels when compared to the Gd-negative (No 6) subgroup, but higher (P = 0.009) than those of the `clinically inactive Gd-positive' (No 16) patients. The sICAM-1 levels did not differ between the two `clinically inactive' subgroups Gd-positive (No 16) and Gd-negative (No 11). Finally the clinically active Gd-negative (No 6) showed sICAM-1 levels higher (P = 0.002) than the clinically inactive Gd-negative (No 11). The specificity of high serum sICAM-1 levels (above M+2 s.d. of control values) to assess the disease activity in MS resulted higher (100%) using clinical than Gd-MRI activity (76%) as gold standard. The changes induced by 1 year recombinant Interferon-b-1b (rIFNb-1b) treatment on sICAM- 1 serum levels were also longitudinally investigated in 36 of the 49 RR MS. sICAM-1 levels at baseline significantly increased in the first 2 months (baseline vs 1st month P50.0001 and 1st vs 2nd month P=0.02), persisted at high levels without any significant change after 3 months, showed a temporary decrease at 6 months, then significantly increased again at 9 and 12 months. Fourteen patients experienced relapses, with a total of 20 relapses, during the whole treatment duration. The mean relapse/rate and the frequency of patients with Gd-positive MRI scans resulted significantly higher in the first semester compared to the second semester of treatment. This study adds further insights into the validity of serum sICAM-1 to assess disease activity in MS and on the immunomodulatory properties of rIFNβ-1b.

Keywords

soluble ICAM-1 Gadolinium-MRI rIFNβ-1b

Get full access to this article

View all access options for this article.

References

Rieckmann P et al. (1995) Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells . J Neuroimmunol 60: 9-15 .

Trojano M et al. (1996) Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings . Neurology 47: 1535-1541 .

Morrisey SP et al. (1996) Partial inhibition of AT-EAE by an antibody to ICAM-1: clinico-histopathological and MRI studies . J Neuroimmunol 69: 85-93 .

Tsukada N et al. (1993) Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type 1-associated myelopathy . Ann Neurol 33: 646-649 .

Rieckmann P et al. (1994) Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse . Neurology 44: 2367-2372 .

Hartung HP et al. (1993) Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis . Neurology 43: 2331-2335 .

Rieckmann P et al. (1997) Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis . Ann Neurol 41: 326-333 .

Jander S , Heidenreich F , Stoll G. (1993) Serum and CSF levels of soluble intercellular adhesion molecule-1 (ICAM-1) in inflammatory neurologic diseases . Neurology 43: 1809-1813 .

Dore-Duffy P et al. (1995) Circulating soluble adhesions proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity . Ann Neurol 37: 55-62 .

10.

Droogan AG et al. (1996) Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1 . J Neuroimmunol 64: 185-191 .

11.

Calabresi PA et al. (1997) Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with Interferon b-1b . Ann Neurol 41: 669-674 .

12.

Trojano M et al. (1995) Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events . JNeurol Neurosurg Psychiatry 58: 300-306 .

13.

Confavreux C et al. (1992) EDMUS, a European database for multiple sclerosis . J Neurol Neurosurg Psychiatry 55: 671-676 .

14.

Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocol . Ann Neurol 13: 227-231 .

15.

Kurtzke JF. (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 33: 1444-1452 .

16.

Schumacher GA et al. (1965) Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of the experimental trials of therapy in multiple sclerosis . Ann NY Acad Sci 122: 552-568 .

17.

Giovannoni G et al. (1997) Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium-enhanced magnetic resonance imaging . Neurology 48: 1557-1565 .